Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Mozhgan Dorkhan & Anders Frid. (2007) A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes. Vascular Health and Risk Management 3:5, pages 721-731.
Read now
Read now
Articles from other publishers (16)
Maoyi Yang, Zhipeng Hu, Lili Zhang & Rensong Yue. (2023) Effects and Mechanisms of Ban-Xia Xie-Xin Decoction on Type 2 Diabetes
Mellitus: Network Pharmacology Analysis and Experimental Evidence. Endocrine, Metabolic & Immune Disorders - Drug Targets 23:7, pages 947-963.
Crossref
Crossref
Theodore R. Rieger, Richard J. Allen & Cynthia J. Musante. (2022) A Quantitative Systems Pharmacology Model of Liver Lipid Metabolism for Investigation of Non-Alcoholic Fatty Liver Disease. Frontiers in Pharmacology 13.
Crossref
Crossref
Iwona Piątkowska-Chmiel, Mariola Herbet, Monika Gawrońska-Grzywacz & Jarosław Dudka. (2022) Regulation of Neuroinflammatory Signaling by PPARγ Agonist in Mouse Model of Diabetes. International Journal of Molecular Sciences 23:10, pages 5502.
Crossref
Crossref
Miao Yu, Guo Yue Yuan, Bin Zhang, Hai Ya Wu & Xiao Feng Lv. (2020) Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis. Diabetes Therapy 11:5, pages 1147-1159.
Crossref
Crossref
Baptist Gallwitz, Samuel Dagogo‐Jack, Vivian Thieu, Luis‐Emilio Garcia‐Perez, Imre Pavo, Maria Yu, Kenneth E. Robertson, Nan Zhang & Francesco Giorgino. (2017)
Effect of once‐weekly dulaglutide on glycated haemoglobin (
HbA1c
) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline
HbA1c
. Diabetes, Obesity and Metabolism 20:2, pages 409-418.
Crossref
Crossref
Carol Wysham, Bruno Guerci, David D'Alessio, Nan Jia & Fady T. Botros. (2016) Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 18:11, pages 1138-1142.
Crossref
Crossref
Verena Benz, Ulrich Kintscher & Anna Foryst-Ludwig. 2012. Sex and Gender Differences in Pharmacology. Sex and Gender Differences in Pharmacology
387
410
.
Giuseppe Derosa. (2011) Pioglitazone is a Valid Alternative to Rosiglitazone. American Journal Cardiovascular Drugs 11:6, pages 357-362.
Crossref
Crossref
Robert R. Henry, John B. Buse, Giorgio Sesti, Melanie J. Davies, Klaus H. Jensen, Jason Brett & Richard E. Pratley. (2011) Efficacy of Anti Hyperglycemic Therapies and the Influence of Baseline Hemoglobin A1C: A Meta-Analysis of the Liraglutide Development Program. Endocrine Practice 17:6, pages 906-913.
Crossref
Crossref
Ming-Chia Hsieh, Kun-Der Lin, Kai-Jen Tien, Shih-Te Tu, Jeng-Yueh Hsiao, Shun-Jen Chang, Shiu-Ru Lin, Shih-Jang Shing & Hung-Chun Chen. (2010) Common polymorphisms of the peroxisome proliferator-activated receptor–γ (Pro12Ala) and peroxisome proliferator-activated receptor–γ coactivator–1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus. Metabolism 59:8, pages 1139-1144.
Crossref
Crossref
R. A. DeFronzo, A. H. Stonehouse, J. Han & M. E. Wintle. (2010)
Relationship of baseline HbA
1c
and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials
. Diabetic Medicine 27:3, pages 309-317.
Crossref
Crossref
R. Chapell, A. L. Gould & C. M. Alexander. (2009) Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone. Diabetes, Obesity and Metabolism 11:11, pages 1009-1016.
Crossref
Crossref
G. Schernthaner. (2009) Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors. International Journal of Clinical Practice 63:6, pages 912-929.
Crossref
Crossref
William C. Hsu. (2009) Consequences of Delaying Progression to Optimal Therapy in Patients with Type 2 Diabetes Not Achieving Glycemic Goals. Southern Medical Journal 102:1, pages 67-76.
Crossref
Crossref
György Jermendy, Diana Erdesz, Laszlo Nagy, Don Yin, Hemant Phatak, Sudeep Karve, Samuel Engel & Rajesh Balkrishnan. (2008) Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary. Health and Quality of Life Outcomes 6:1.
Crossref
Crossref
Surendra K. Sharma, Jing Ping Yeo & Alan Garber. (2008) Lessons in initiating insulin in clinical practice. Diabetes Research and Clinical Practice 81, pages S16-S22.
Crossref
Crossref